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ABSTRACT 
Hepatocellular carcinoma (HCC) represents the fifth and ninth cause of mortality among male and female 
cancer patients, respectively and typically arises on a background of a cirrhotic liver. HCC develops in a 
multi-step process, often encompassing chronic liver injury, steatosis and cirrhosis eventually leading to the 
malignant transformation of hepatocytes. Aberrant expression of the class I homeobox gene family (HOX), 
a group of genes crucial in embryogenesis, has been reported in a variety of malignancies including solid 
tumors. Among HOX genes, HOXA13 is most overexpressed in HCC and is known to be directly regulated 
by the long non-coding RNA HOTTIP. In this study, taking advantage of a tissue microarray containing 305 
tissue specimens, we found that HOXA13 protein expression increased monotonically from normal liver to 
cirrhotic liver to HCC and that HOXA13-positive HCCs were preferentially poorly differentiated and had 
fewer E-cadherin-positive cells. In two independent cohorts, patients with HOXA13-positive HCC had worse 
overall survival than those with HOXA13-negative HCC. Using HOXA13 immunohistochemistry and 
HOTTIP RNA in situ hybridization on consecutive sections of 16 resected HCCs, we demonstrated that 
HOXA13 and HOTTIP were expressed in the same neoplastic hepatocyte populations. Stable 
overexpression of HOXA13 in liver cancer cell lines resulted in increased colony formation on soft agar and 
migration potential as well as reduced sensitivity to sorafenib in vitro. Our results provide compelling 
evidence of a role for HOXA13 in HCC development and highlight for the first time its ability to modulate 
response to sorafenib. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) represents the fifth and ninth cause of mortality among male and female 
cancer patients, respectively1, 2 and typically arises on a background of a cirrhotic liver.3 HCC develops in a 
multi-step process, often encompassing chronic liver injury, steatosis and cirrhosis eventually leading to the 
malignant transformation of hepatocytes.4 HCC is unique among cancers, in that no standard first-line 
cytotoxic therapy is routinely used in the clinic 5 and limited therapeutic choices are available.6, 7 Currently, 
the multi-tyrosine kinase inhibitor sorafenib is the only option for HCCs in advanced stages. Of note, there 
are no validated predictive biomarkers for sorafenib response in HCC.8 
 
Class I homeobox gene family (HOX) consists of a group of 39 highly conserved transcription factors 
known for their role as master regulators of embryonic development.9 The HOX genes are distributed over 
4 chromosomal regions each containing between 9 and 11 members that aligned into 13 paralogous 
groups.10, 11 During developmental phases, HOX genes regulate the formation of distinct anatomical 
regions, through the maintenance of spatio-temporal collinearity across the anterior-posterior body axis.12-14 
By contrast, in adult tissues, HOX genes maintain homeostasis by preserving the coordinates established 
during embryonic growth.15, 16 
 
Aberrant expression of the HOX genes has been reported in a variety of malignancies including solid 
tumors.17-21 Among HOX genes, HOXA13 has been reported to be the most deregulated in HCC.22-25 An 
earlier study found that knocking down HOXA13 reduces anchorage-dependent growth in vitro and cancer 
cell growth in mice with esophageal squamous cell carcinoma.26 Moreover, upregulation of HOXA13 has 
been linked to the activation of the Wnt and TGF-β pathways,21 suggesting that HOXA13 may play a role in 
determining the aggressiveness of HCCs. Furthermore, we recently reported that HOXA13 is directly 
regulated by the long non-coding RNA (lncRNA) HOXA transcript at the distal tip (HOTTIP), located in 
physical contiguity with HOXA13, via the interaction with the WDR5/MLL complex.22 Notably, HOXA13 and 
HOTTIP co-expression was found to be associated with disease progression, metastasis formation and 
worse clinical outcome,22 thus suggesting that the molecular axis controlled by HOXA13 and HOTTIP plays 
a pivotal role in HCC progression.22  
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In this study, we sought to determine whether HOXA13 is expressed at the protein level and whether its 
expression is associated with prognosis. We also evaluated the effect of HOXA13 on sorafenib response in 
vitro using stable liver cancer cell lines with either overexpression or knockdown of HOXA13. 
 
MATERIALS AND METHODS 
Tissue microarray data and patient samples  
Tissue microarray (TMA) was constructed from formalin-fixed and paraffin-embedded (FFPE) specimens 
using a custom-built instrument (Beecher Instruments, Silver Spring, MD) as previously described.27 
Specimens were mostly collected from patients with early stage disease who were eligible for and 
underwent surgical resection without prior treatment. The TMA contained 434 tissue specimens of which 
305 were suitable for evaluation, which included 115 HCC, 82 cirrhotic liver and 108 normal liver samples 
(Supplementary Table S1). Exclusion criteria from the analysis were the absence of tissue punch, poor 
HOXA13 immunostaining quality or the lack of comprehensive clinical data. Tissue samples were retrieved 
from the archives of the Institute of Pathology, University Hospital Basel, Switzerland. Histologic grading 
and classification of HCCs and non-neoplastic liver tissue samples was performed by two experienced 
pathologists with an expertise in liver pathology (M.S.M. and L.M.T.) according to the World Health 
Organization (WHO) guidelines28 and the Edmondson & Steiner grading system.29 Additionally, samples 
were classified using the Barcelona Clinic Liver Cancer (BCLC) staging classification.30 A second cohort of 
samples comprising whole sections from 43 resected HCC samples from sorafenib-treated patients was 
obtained from the Unit of Pathology, University of Milan and Humanitas Clinical and Research Center, 
Milan, Italy (Supplementary Table S2). Histologic grading and classification of this cohort of samples was 
performed by three experienced pathologists (C.N., M.R. and L.M.T.) as described for the TMA cohort. The 
study was approved by the institutional review boards of the respective authors’ institutions. 
 
Immunohistochemistry 
Immunohistochemical (IHC) staining for HOXA13 and E-cadherin was performed on 4 µm sections of FFPE 
tissue using primary antibodies against HOXA13 (Abcam, Cambridge, UK; clone ab106503, dilution 1:200) 
and E-cadherin (Cell Marque, Rocklin, CA; clone EP000Y, ready-to-use). Specifically, sections were pre-
treated with CC1 (Ventana Medical Systems, Tucson, AZ) and incubated with primary antibodies against 
HOXA13 and E-cadherin. Staining procedures were performed on a Benchmark immunohistochemistry 
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staining system (Ventana Medical Systems, Tucson, AZ) using iVIEW-DAB as chromogen as previously 
described.31 Positive and negative controls were included in each run. Immunoreactivity was scored by two 
experienced pathologists (M.S.M. and L.M.T.) For HOXA13, TMA specimens (tissue punches) were 
analyzed by evaluating the staining intensity (0-3, Figure 1a). For HOXA13 on whole tissue sections using 
at least two non-consecutive fields, both the staining intensity (0-3) and the percentage of stained cells (i.e. 
hepatocytes) were evaluated as described by Allred et al.32 and classified as HOXA13-high and HOXA13-
low using a semi-quantitative score accounting for both staining intensity and the percentage of stained 
cells using the following formula: 
((-x0*25) + (x1*20+ x2*30+ x3*50)*75))/100 
where xi is the percentage of cells with intensity i. Sample with positive and negative scores were classified 
as HOXA13-high and HOXA13-low, respectively. 
 
Analysis of putative HOXA13 binding sites on CDH1 promoter 
The promoter sequence of the human CDH1 gene (encoding E-cadherin, Unigene ID: Hs.461086, ID of 
transcript: NM_004360) was retrieved from the DataBase of Transcriptional Start Site (DBTSS, http://dbtss-
old.hgc.jp/hg19_mm9/), encompassing the genomic regions 2000bp upstream to 400bp downstream of the 
CDH1 transcriptional start site. The CDH1 promoter sequence was scanned for the presence of putative 
binding sites of HOXA13 using the JASPAR algorithm33 (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl) and 
the frequency matrix model (MA0650.1) corresponding to the human HOXA13 (Supplementary Figure 
S1a). The default relative score cut-off of 0.8 was used. Based on the results from JASPAR, a graphical 
representation of the distribution of putative binding sites of HOXA13 on the promoter region of CDH1 gene 
was obtained using ConSite service (http://consite.genereg.net/). 
 
HOTTIP RNA in situ hybridization 
Single color RNA in situ hybridization (ISH) was performed using the RNAscope® 2.0 HD Red 
Chromogenic Reagent Kit (Advanced Cell Diagnostics, Newark, CA) per the manufacturer’s guidelines. 
Paired double-Z oligonucleotide probes were designed against Hs-HOTTIP RNA (Catalog number 400133, 
Advanced Cell Diagnostics, Newark, CA) using custom software as described previously.34 GenBank 
accession numbers, number of probe pairs, and probe regions are: NR_037843, 20 pairs, nucleotides 388-
1386. 4 µm sections of FFPE tissue were incubated at 60°C for 1 hr prior to use. After de-paraffinization 
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and dehydration, the tissues were air-dried and treated with peroxidase blocker before boiling at 100-104°C 
in a pre-treatment solution for 15 min. Protease was then applied at 40°C for 30 min. Target probes were 
hybridized at 40°C for 2 hrs. All hybridizations were performed in a HybEZ system (Advanced Cell 
Diagnostics, Newark, CA) at 40°C. Hybridization signals were detected by chromogenic precipitate 
development and RNA staining signal was identified as red dots. Following the RNAscope assay, samples 
were counterstained for 2 min with 50% Gill’s Hematoxylin diluted in dH2O. Each sample was quality 
controlled for RNA integrity with a probe specific to the housekeeping gene cyclophilin B (PPIB); only 
samples with an average of >4 dots per cell were included for analysis. Negative control background 
staining was evaluated using a probe specific to the bacterial dapB gene. To verify that the RNAscope 
method was performed with technical accuracy, references slides consisting of FFPE HeLa cells were 
tested with PPIB and dapB in parallel with tissue samples. Staining intensity was scored on the 4-point 
scale (i.e. 0-3) by two experienced pathologists (M.S.M and L.M.T.) as for HOXA13 IHC staining intensity. 
 
Cell lines maintenance and generation of stable clones 
Liver cancer-derived cell lines SNU-449 and HepG2 were obtained from the Laboratory of Experimental 
Carcinogenesis (Bethesda, MD), authenticated by short tandem repeat profiling as previously described35 
and tested for mycoplasma infection using a PCR-based test (ATCC). All cell lines were maintained under 
the condition as recommended by the provider. Total RNA and proteins were extracted from cells at 75% 
confluence using TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacture’s guidelines. SNU-449 
and HepG2 cells were transfected as described by Wang et al.36 to generate stable HOXA13-expressing 
cell lines.  
 
Stable HOXA13 knockdown cells were obtained using the TALEN. Specifically, 13x104 cells were plated in 
6-well plate and after 24 hr cells were transfected with lipofectamine3000 (Thermo Fisher Scientific, 
Reinach, CH) according to the manufacturer’s procedure with pcDNA3.1+ containing the full-length human 
cDNA of HOXA13 and empty vector as control.22 The cells were selected with 50 ug/ml of G418 (Gibco) for 
72 hrs. For the knocking down of HOXA13, SNU-449 and HepG2 were simultaneously transfected with 
TAL2209/2209, a gift from Keith Joung (plasmids # 36672 and #36671, Addgene, Cambridge, MA).37 24 
hrs after transfection, cells were plated in 96-well plate using a dilution of 1 cell/well. 
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Relative expression of HOXA13 by qRT-PCR 
cDNA was synthesized from 1 μg of total RNA using Superscript II RNase H-reverse transcriptase 
(Invitrogen, Carlsbad, CA). HOXA13 expression was assessed using the TaqMan® Probe-Based Gene 
Expression Analysis (Applied Biosystems, Foster City, CA; probe Hs00426284_m1). Measurements were 
normalized using GAPDH and 18S levels as reference. The fold change in gene expression was calculated 
using the standard ∆∆Ct method as previously described.23, 38 All reverse-transcriptase reactions, including 
no-template controls, were run on an Applied Biosystem 7900HT thermocycler. All samples were analyzed 
in triplicate. 
 
Soft-agar colony assay, proliferation assay and in vitro sorafenib exposure  
Soft agar colony formation assay was performed as previously described.39 Specifically, 103 cells were 
plated in 60mm dishes in a solution containing Dulbecco’s modified Eagle’s medium 2X (Thermo Fisher 
Scientific, Foster City, CA), TPB Buffer (Thermo Fisher Scientific) and 1.25% of Noble Agar (Difco, Franklin 
Lakes, NJ). Cells were harvested and counted, and a layer of 7ml solution containing Noble Agar was left 
to polymerize on the bottom of the dishes. Meanwhile cells were diluted in 2ml of the same solution, plated 
and left growing for 2 weeks in the incubator. Pictures of four different fields were taken using an inverted 
microscope and cell colonies were counted and measured in size using the ImageJ software (Version 
1.49). Colonies were classified into three groups based on thresholds defined using the size distribution 
(arbitrary units) of the control group as small (first quartile), medium (2nd and 3rd quartiles) and large (4th 
quartile).  
 
Cell proliferation was assayed using the xCELLigence system (RTCA, ACEA Biosciences, San Diego, CA). 
Background impedance of the xCELLigence system was measured for 12 sec using 50 μL of room 
temperature cell culture media in each well of E-plate 16. SNU-449 and HepG2 cells were grown and 
expanded in tissue culture flasks as previously described.40 After reaching 75% confluence, the cells were 
washed with PBS and detached from the flasks using a short treatment with trypsin/EDTA. 10,000 cells 
were dispensed into each well of an E-plate 16. Growth and proliferation of the cells were monitored every 
15 min up to 72 hrs via the incorporated sensor electrode arrays of the xCELLigence system, using the 
RTCA-integrated software according to the manufacturer’s parameters. 
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In vitro sorafenib exposure experiments were carried out as described by Rothweiler et al.41 Briefly, cells 
were grown as above and 24 hrs after cell seeding, sorafenib at final concentration of 10 μM or 20 μM or 
DMSO (0.1% v/v) was added. Cell growth was assayed for up to 72 hours. Data analysis and data 
normalization to the time before sorafenib/ DMSO addition was carried out using the RTCA Software 
1.2.1.1002. Cell index values from 3 replicate experiments were normalized to DMSO, which was set as 
100%. 
 
Migration Assay.  
Migration assay was performed with CIM plates using the xCELLigence technologies (OLS OMNI Life 
Science, Basel, Switzerland). Stably transfected cells were detached and counted. 3x104 cells were plated 
in each well according to manufacturer’s instruction and migration was assessed 12, 24 and 36 hrs after 
seeding. 
 
Statistical analysis 
For statistical analysis, the Chi-squared test (χ2 test) and Fisher's exact test for categorical variables and 
Mann-Whitney U/multiple t-tests/t-tests for continuous variables were used. Patient survival was assessed 
using the Kaplan–Meier method and analyzed using the log-rank test. Correlation tests were performed 
using Spearman correlation. All tests were two-sided and P-values ≤0.05 were considered statistically 
significant. Analyses were performed using GraphPad 6.0 (Prism, La Jolla, CA) and SPSS (version 24, 
IBM, San Francisco, CA). 
 
RESULTS 
HOXA13 protein is increased in poorly differentiated and more aggressive HCCs 
In a previous study, our group reported an upregulation of the RNA expression levels of the HOXA13 gene 
in the majority of HCCs analyzed.22  To corroborate and to extend this finding to the protein level, we 
investigated, by means of IHC on a TMA, HOXA13 levels on a large cohort of HCC (n=115), cirrhotic liver 
(n=108) and normal liver (n=82) specimens (Supplementary Table S1). Samples were evaluated according 
to their staining intensity (Figure 1a). Our analysis revealed that HOXA13 was expressed (i.e. intensities 1, 
2 or 3) in 10% (8/82) of normal liver, 18% (19/108) of cirrhotic liver and 42% (48/115) of HCC specimens 
with a monotonic increase from normal liver tissues to cirrhotic tissues to HCCs (P <0.001, Chi-squared 
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test, Figure 1b). Stratification based on the individual HOXA13 IHC intensity scores in HCCs showed that 
those with high HOXA13 expression (intensity 3) were associated with the highest proportion (29%) of 
poorly differentiated tumors (P <0.001, Chi-squared test, Figure 1c). Altogether, these results highlighted 
that: i) HOXA13 positivity is more frequent in HCCs compared to normal and cirrhotic livers and ii) high 
HOXA13 expression is associated with high tumor grade.  
 
Considering our previous finding that HOXA13 expression was associated with metastasis in HCC,22 we 
evaluated the expression of E-cadherin, a master regulation of the metastatic process,42 in the same set of 
samples. We observed that HOXA13-positive HCCs had lower percentages of E-cadherin-positive cells 
compared to HOXA13-negative HCCs, cirrhotic liver and normal liver specimens (mean of positive cells 
48% vs 65%, 68% and 69%, respectively, all P <0.05, Mann-Whitney U tests, Figure 1d). Stratification of 
HCCs based on HOXA13 staining intensity scores showed that E-cadherin levels were inversely correlated 
with HOXA13 expression (all P <0.05, Mann-Whitney U tests, Figure 1e).  
 
To determine if there is a causal link between the inverse expression pattern of HOXA13 and E-cadherin, 
we performed in silico and in vitro experiments to determine if HOXA13 could directly regulate the 
expression of E-cadherin (encoded by CDH1). Using the JASPAR algorithm33, we identified several 
putative HOXA13 binding sites on the CDH1 promoter sequence, in particular in the region 2000bp to 
500bp upstream of the CDH1 transcriptional start site (Supplementary Figure S1), suggesting that HOXA13 
may directly interact with the CDH1 promoter. Indeed, upon stable overexpression of HOXA13 in the HCC 
HepG2 cell line, we observed a decrease in E-cadherin and, conversely, an increase in N-cadherin 
expression (Figure 1f). In line with a previously published report43, our in silico and in vitro experiments 
suggest a possible role for HOXA13 in the regulation of epithelial-to-mesenchymal transition in directly 
binding to E-cadherin. 
 
Taken together, these results suggest that HOXA13 overexpression is associated with a more 
undifferentiated and aggressive tumor phenotype in HCC and we provided additional evidences that 
HOXA13 may regulate E-cadherin. 
 
HOXA13 protein level is associated with HCC patient survival  
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To explore whether HOXA13 protein levels were associated with the outcome of HCC patients as we 
previously demonstrated for HOXA13 mRNA levels,22 we examined the patient overall survival (OS) and 
disease-free survival (DFS) for our cohort of TMA HCC samples (n=115, Supplementary Table S1). 
Patients with HOXA13-positive HCC had shorter OS compared to those with HOXA13-negative disease 
(median 52 vs 65 months, P =0.03, log-rank test, Figure 2a). However, we found no statistical difference in 
DFS between patients with HOXA13-positive and HOXA13-negative HCC (median 16 vs 20 months, P 
=0.33, log-rank test, Supplementary Figure S2a). Similarly, comparing the OS and DFS stratified according 
to HOXA13 IHC staining intensities demonstrated that patients with HCCs with the highest IHC intensity 
(i.e. 3) had the worst OS, but no difference was observed in DFS (P =0.04 and P =0.24, respectively, log-
rank tests, Figure 2b and Supplementary Figure S2b). Focusing on patients with BCLC grade C HCC, since 
this is the only group eligible for sorafenib treatment, we found that patients with HOXA13-positive HCC 
had worse OS than those with HOXA13-negative disease (median 20 vs 24 months, P =0.05, log-rank test, 
Figure 2c). 
 
To extend these results to sorafenib-treated patients, we obtained whole tissue sections of an independent 
cohort composed of late stage sorafenib-treated HCCs (Supplementary Table S2) and classified them as 
HOXA13-high and –low based on a semi-quantitative score, taking into account the staining intensity and 
the proportion of positive cells (Methods). In accordance with the results obtained from patients with 
untreated HCCs, sorafenib-treated patients with HOXA13-positive HCCs showed decreased OS compared 
to patients with HOXA13-negative disease (median 31 vs 41 months, P =0.05, log-rank test, Figure 2d).  
 
These results suggest the HOXA13 protein expression in HCC is associated with OS in patients treated or 
untreated with sorafenib. 
 
HOXA13 expression overlaps with HOTTIP in HCC samples 
Based on gene expression array data, we previously showed that HOXA13 overexpression in HCC is 
associated with concomitant HOTTIP upregulation.22 To determine whether HOXA13 is upregulated in the 
same population of cells as HOTTIP, we performed HOXA13 IHC and HOTTIP RNA in situ hybridization 
(ISH) on consecutive sections of 16 resected HCCs from the sorafenib-treated cohort (Supplementary 
Table S2). We found that both HOXA13 and HOTTIP were heterogeneously expressed in 71% of cases 
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analyzed. Comparing the expression patterns, we observed that HOXA13 and HOTTIP were expressed in 
virtually the same populations of hepatocytes (Figure 3a) and that the percentages of HOXA13-positive and 
HOTTIP-positive cells demonstrated a significant correlation (r =0.91, P <0.0001, Spearman correlation 
test, Figure 3b-c). 
 
HOXA13 overexpression enhances cell aggressiveness in vitro 
In line with the observations that HOXA13 expression is increased in HCCs compared to non-tumoral livers   
and in poorly differentiated HCCs compared to moderately and well differentiated HCCs, our previous 
results demonstrated that transient in vitro HOXA13 overexpression in liver cancer cells resulted in 
increased proliferation whereas HOXA13 inhibition strongly reduced cell proliferation.22 Therefore, we 
sought to investigate if stable ectopic HOXA13 overexpression would have oncogenic properties in in vitro 
models. We generated liver cancer-derived cell line SNU-449 clones that stably overexpressed HOXA13, 
as verified by qRT-PCR (Supplementary Figure S3a). To test whether the cells that overexpressed 
HOXA13 displayed a more aggressive phenotype, we performed a colony formation assay on soft agar and 
evaluated the number and size of the resulting colonies (Figure 4a). Compared to the untransfected cell 
lines and the empty vector controls, SNU-449 overexpressing HOXA13 displayed larger colonies (P <0.05, 
Mann-Whitney U test, Figure 4b) and a higher number of colonies per analyzed field (P <0.05, Mann-
Whitney U test, Figure 4c). Additionally, we performed a migration assay on SNU-449 and HepG2 stably 
overexpressing HOXA13 and observed that forced expression of HOXA13 resulted in increased cell 
migration (both P<0.05, Figure 4 d-e) in both cell lines, thus supporting and corroborating our hypothesis 
that HOXA13 promotes epithelial-to-mesenchymal transition. 
 
Taken together our results suggest that, in addition to increasing cell proliferation, HOXA13 overexpression 
also enhances cell aggressiveness and migration in vitro. 
 
HOXA13 level modulates sorafenib sensitivity in vitro  
To provide a functional basis for our observation that sorafenib-treated patients with high HOXA13 levels in 
their HCCs had worse survival, we sought to investigate the impact of HOXA13 modulation in HCC-derived 
cell lines upon sorafenib exposure in vitro. In addition to the liver cancer-derived cell lines (SNU-449 and 
HepG2) with stable HOXA13 overexpression using pCMV-vector, we also generated two cell lines (SNU-
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449 and HepG2) with HOXA13 knockdown using TALEN, as verified by qRT-PCR (Supplementary Figure 
S3). To define the appropriate dose of sorafenib in vitro, we performed a titration experiment using 
untransfected SNU-449 and HepG2 (Supplementary Figure S4) and observed a significant inhibition of cell 
viability at 20 μM sorafenib compared to other concentrations (P <0.05, multiple t-test, Supplementary 
Figure S4). We then compared the proliferation indices of treated and untreated cells with and without 
HOXA13 overexpression using the xCelligence system up to 72 hours after sorafenib exposure. In 
accordance with our previous results,22 in the absence of sorafenib, HOXA13-overexpressing cells 
displayed increased cell proliferation compared to the vector control (P <0.01, multiple t-test, Figure 5a/c). 
By contrast, sorafenib treatment significantly reduced cell proliferation in the vector control but had no effect 
in HOXA13-overexpressing cells (P <0.01 and P >0.05, respectively, multiple t-tests, Figure 5a/c).  
 
Conversely, when we compared the untreated cells with and without HOXA13 knockdown, HOXA13-
knockdown cells had lower cell proliferation than cells with TALEN control in both SNU-449 and HepG2 
(both P <0.01, multiple t-tests, Figure 5b/d). On the other hand, upon sorafenib exposure, cell proliferation 
was significantly reduced in HOXA13 knockdown cells compared to the cells with TALEN control in both 
cell lines (both P <0.01, multiple t-tests, Figure 5b/d). Overall, these results provide evidence that 
overexpression of HOXA13 modulates sorafenib response in HCC in vitro models. 
 
DISCUSSION  
In this study, we reported that HOXA13 protein level increased monotonically from normal liver to cirrhotic 
liver to HCC. We also observed that HOXA13-positive HCCs were preferentially poorly differentiated and 
had fewer E-cadherin-positive cells. In addition, we demonstrated that HOXA13 positivity is associated with 
worse overall survival, but not disease-free survival, which we confirmed in a second cohort consisting of 
sorafenib-treated patients. Furthermore, we showed that HOXA13 and HOTTIP were co-expressed in the 
same population of neoplastic hepatocytes in HCC. Finally, using liver cancer-derived cell lines, we 
demonstrated that HOXA13 expression enhances cell aggressiveness and modulates sorafenib response 
in vitro.  
 
Based on gene expression data, we previously reported that HOXA13 is significantly upregulated in HCC.22, 
23 In this work, by analyzing a large cohort of HCC samples (n=115), we extended our results to the protein 
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level showing consistent HOXA13 overexpression in HCCs. This observation complements our previous 
results on the mRNA level,22, 23 is in line with the findings of another group on the protein level24 and further 
highlights that HOXA13 is deregulated in a subgroup of poorly differentiated (i.e. high Edmondson grade) 
HCCs. Additionally, we observed that HOXA13-positive HCCs harbored fewer E-cadherin-positive cells. 
The loss of E-cadherin has been linked to the formation of metastases through the process of epithelial-to-
mesenchymal transition44 and several groups recently reported that HOXA13 expression promotes cell 
invasive properties, for instance in glioma by activating the Wnt and TGF-β pathways.21 Our observation of 
HOXA13-positive HCCs displaying a more aggressive phenotype is thus in line with our previously 
described association between high HOXA13 level and metastatic incidence22 and the association with 
worse prognosis in terms of OS in these patients. HOXA13 positivity has been associated with unfavorable 
survival in HCCs24 as well as in other tumor entities such as esophageal squamous cell carcinoma,26, 45 
gastric cancer46 and paediatric acute lymphoblastic leukaemia.18, 47, 48 In contrast to the previous study in 
which the authors found associations of HOXA13 expression with both OS and DFS,24 we found that 
HOXA13 expression was only associated with unfavorable OS, but not DFS, in two independent cohorts, 
one of which was a cohort of patients with sorafenib-treated, late-stage disease. 
 
The results from our in vitro experiments provide functional evidence for the association observed between 
HOXA13 overexpression and the more aggressive and less differentiated phenotype in HCCs. We 
observed loss of E-cadherin upon HOXA13 overexpression and identified putative HOXA13 binding sites in 
the CDH1 promoter, suggesting that HOXA13 may have a direct role in the regulation of E-cadherin 
expression. Additionally, we observed increased colony formation and migration potential in cell lines 
overexpressing HOXA13, demonstrating that HOXA13 confers a more aggressive phenotype. In terms of 
sensitivity to sorafenib, forced expression of HOXA13 resulted in reduced sensitivity in vitro whereas 
knockdown of HOXA13 had the opposite effect. Given the role of HOXA13 in regulating E-cadherin and the 
previously published results49 suggesting that epithelial-to-mesenchymal transition plays a pivotal role in 
modulating drug resistance, one can speculate that HOXA13 may affect sensitivity to sorafenib through the 
regulation of the epithelial-to-mesenchymal transition process. Indeed, the reduced sensitivity to sorafenib 
may be related to the loss of E-cadherin and hence an epithelial phenotype. Conversely, upregulation of 
HOXA13 may also affect drug response to multiple drugs in multiple cancer types as HOXA13 
overexpression has also been reported to result in gemcitabine resistance in pancreatic cancer.43 These 
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results provide a functional basis for the suboptimal response of the subset of patients with HOXA13-
positive disease and the observed reduced OS in this group of patients.  
 
Several studies previously demonstrated that HOXA13 and HOTTIP expression are highly correlated.50-53 
Specifically, we reported that HOTTIP activates HOXA13 through epigenetic mechanisms including DNA 
methylation and histone modifications22 and Wang et al. described that, in the Cs12 gastric cells, HOTTIP 
knockdown attenuates the recruitment of WDR5 and MLL1 and promotes DNMT3B localization on the 
HOXA13 promoter.50 Here by analyzing HOXA13 IHC and HOTTIP ISH on consecutive HCC sections, we 
showed that HOXA13 and HOTTIP displayed intra-tumor heterogeneous pattern of expression and their 
concomitant overexpression was found in the same populations of transformed hepatocytes. To the best of 
our knowledge, this is the first in situ characterization of the pattern of HOTTIP expression in human 
tissues. Given the increased recognition of the role of lncRNAs in cancer,54 this observation and the 
technique are of significant interest. We foresee that in situ characterization of HOTTIP expression will 
enable the identification of the specific subpopulations of transformed or malignant cells that express 
HOTTIP.  
 
There are several limitations to our study. Our first and larger cohort of resected samples consisted of TMA 
punches rather than whole sections, and thus the observed expression may not be representative of the 
individual tissue samples. To account for intra-tumor heterogeneous expression of HOXA13, for the second 
cohort for which whole sections were available, we used a semi-quantitative score that accounts for both 
staining intensity and the percentage of cells for each staining intensity. In addition, the number of patients 
with BCLC stage C disease and late-stage sorafenib-treated patients for survival analysis was small. It 
should be noted that, despite the small cohorts, we saw a consistent association of HOXA13 
overexpression with worse prognosis in both cohorts. It should also be noted that access to such 
collections of specimens with the associated outcome data is extremely limited. Finally, our results have not 
provided mechanistic insight into the association of HOXA13, HOTTIP and E-cadherin expression and the 
effect of HOXA13 expression on sorafenib sensitivity. Although we found that HOTTIP and HOXA13 are 
expressed in same population of cells, we have not provided direct evidence to support the hypothesis that 
HOTTIP regulates HOXA13 expression. Due to the cis-regulatory mechanism of HOTTIP, the physical 
proximity of HOTTIP to the HOX genes (including HOXA13) on the genome is essential for its regulatory 
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activity. Indeed, it has been demonstrated by,36 that ectopic HOTTIP expression driven by retroviral 
insertion sites scattered randomly throughout the genome is not sufficient to induce 5’ HOXA genes. Future 
experiments using genome editing technology to investigate the regulatory role of HOTTIP would be of 
great interest. 
 
To conclude, using a combination of clinico-pathologic and protein expression data obtained from two 
independent cohorts of HCC patients, as well as in vitro experiments, we provided evidence for a role of the 
molecular axis comprising HOXA13/HOTTIP in HCC development and response to sorafenib.   
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FIGURES LEGENDS 
Figure 1: HOXA13 is expressed in a subset of aggressive HCCs and is inversely correlated with E-
cadherin expression. (a) Representative micrographs of HOXA13 IHC with different staining intensities. 
(b) Percentages of HOXA13-positive and-negative normal, cirrhotic and tumoral livers. (c) HOXA13 
intensity in poorly, moderately and well differentiated HCCs. (d) E-cadherin expression levels in normal, 
cirrhotic, HOXA13-negative and HOXA13-positive tumoral livers. (e) E-cadherin expression levels in 
normal, cirrhotic and tumoral livers according to HOXA13 intensities. (f) E-cadherin and N-cadherin protein 
levels upon overexpression of HOXA13 in HepG2 cell lines. P-values ≤0.05 were considered statistically 
significant. *: P-values ≤0.05; Error bars, s.d. of the mean. 
 
Figure 2: High HOXA13 expression is associated with poor overall survival in patients with HCC. 
Overall survival of 115 HCC patients, (a) stratified into HOXA13-negative (staining intensity 0) and 
HOXA13-positive (staining intensity 1/2/3) or (b) stratified according to HOXA13 staining intensities. (c) 
Overall survival of 26 BCLC stage C HCC patients stratified into HOXA13-negative (staining intensity 0) 
and HOXA13-positive (staining intensity 1/2/3). (d) Overall survival of 43 HCC sorafenib-treated patients, 
stratified into HOXA13-negative (staining intensity 0) and HOXA13-positive (staining intensity 1/2/3). 
Statistical comparisons were performed using log-rank tests. P-values ≤0.05 were considered statistically 
significant. 
 
Figure 3: HOXA13 and HOTTIP expression patterns in HCC. (a) Representative micrographs of 
HOXA13 IHC and HOTTIP ISH stained HCCs. (b) Heat map displaying the percentage of HOXA13-positive 
and HOTTIP-positive cells. (c) Spearman correlation analysis performed for the percentages of HOTTIP-
positive and HOXA13-positive cells. 
 
Figure 4: Effect of HOXA13 overexpression on cell transformation in in vitro models. (a) 
Representative micrographs of colonies, (b) distribution of sizes of the colonies and (c) number of colonies 
per field in control SNU-449 cells and SNU-449 cells stably overexpressing HOXA13. (d-e) Migration 
potential in SNU-449 and HepG2 cell lines at 12,24 and 36hrs in stable HOXA13 overexpressing cells. All 
experiments were performed in triplicates. Error bars, s.d. of the mean. Statistical comparisons were 
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performed using unpaired t-tests with Welch correction. P ≤0.05 were considered statistically significant. *: 
P ≤0.05; ns: not significant. 
 
Figure 5: HOXA13 modulates sorafenib response in HCC cells. Effect of sorafenib treatment in cells 
with (a-c) stable overexpression of HOXA13 (SNU-449 and HepG2) or (b-c) knockdown of HOXA13 (SNU-
449 and HepG2) compared to the untransfected controls. Quantification was performed using a 
spectrophotometer. All experiments were performed in triplicates. Error bars, s.d. of the mean. Statistical 
comparisons were performed using Holm-Šídák-corrected multiple t tests an. P ≤0.05 were considered 
statistically significant. **: P ≤0.01. 
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ABSTRACT 
Hepatocellular carcinoma (HCC) represents the fifth and ninth cause of mortality among male and female 
cancer patients, respectively and typically arises on a background of a cirrhotic liver. HCC develops in a 
multi-step process, often encompassing chronic liver injury, steatosis and cirrhosis eventually leading to the 
malignant transformation of hepatocytes. Aberrant expression of the class I homeobox gene family (HOX), 
a group of genes crucial in embryogenesis, has been reported in a variety of malignancies including solid 
tumors. Among HOX genes, HOXA13 is most overexpressed in HCC and is known to be directly regulated 
by the long non-coding RNA HOTTIP. In this study, taking advantage of a tissue microarray containing 305 
tissue specimens, we found that HOXA13 protein expression increased monotonically from normal liver to 
cirrhotic liver to HCC and that HOXA13-positive HCCs were preferentially poorly differentiated and had 
fewer E-cadherin-positive cells. In two independent cohorts, patients with HOXA13-positive HCC had worse 
overall survival than those with HOXA13-negative HCC. Using HOXA13 immunohistochemistry and 
HOTTIP RNA in situ hybridization on consecutive sections of 16 resected HCCs, we demonstrated that 
HOXA13 and HOTTIP were expressed in the same neoplastic hepatocyte populations. Stable 
overexpression of HOXA13 in liver cancer cell lines resulted in increased colony formation on soft agar and 
migration potential as well as reduced sensitivity to sorafenib in vitro. Our results provide compelling 
evidence of a role for HOXA13 in HCC development and highlight for the first time its ability to modulate 
response to sorafenib. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) represents the fifth and ninth cause of mortality among male and female 
cancer patients, respectively1, 2 and typically arises on a background of a cirrhotic liver.3 HCC develops in a 
multi-step process, often encompassing chronic liver injury, steatosis and cirrhosis eventually leading to the 
malignant transformation of hepatocytes.4 HCC is unique among cancers, in that no standard first-line 
cytotoxic therapy is routinely used in the clinic 5 and limited therapeutic choices are available.6, 7 Currently, 
the multi-tyrosine kinase inhibitor sorafenib is the only option for HCCs in advanced stages. Of note, there 
are no validated predictive biomarkers for sorafenib response in HCC.8 
 
Class I homeobox gene family (HOX) consists of a group of 39 highly conserved transcription factors 
known for their role as master regulators of embryonic development.9 The HOX genes are distributed over 
4 chromosomal regions each containing between 9 and 11 members that aligned into 13 paralogous 
groups.10, 11 During developmental phases, HOX genes regulate the formation of distinct anatomical 
regions, through the maintenance of spatio-temporal collinearity across the anterior-posterior body axis.12-14 
By contrast, in adult tissues, HOX genes maintain homeostasis by preserving the coordinates established 
during embryonic growth.15, 16 
 
Aberrant expression of the HOX genes has been reported in a variety of malignancies including solid 
tumors.17-21 Among HOX genes, HOXA13 has been reported to be the most deregulated in HCC.22-25 An 
earlier study found that knocking down HOXA13 reduces anchorage-dependent growth in vitro and cancer 
cell growth in mice with esophageal squamous cell carcinoma.26 Moreover, upregulation of HOXA13 has 
been linked to the activation of the Wnt and TGF-β pathways,21 suggesting that HOXA13 may play a role in 
determining the aggressiveness of HCCs. Furthermore, we recently reported that HOXA13 is directly 
regulated by the long non-coding RNA (lncRNA) HOXA transcript at the distal tip (HOTTIP), located in 
physical contiguity with HOXA13, via the interaction with the WDR5/MLL complex.22 Notably, HOXA13 and 
HOTTIP co-expression was found to be associated with disease progression, metastasis formation and 
worse clinical outcome,22 thus suggesting that the molecular axis controlled by HOXA13 and HOTTIP plays 
a pivotal role in HCC progression.22  
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In this study, we sought to determine whether HOXA13 is expressed at the protein level and whether its 
expression is associated with prognosis. We also evaluated the effect of HOXA13 on sorafenib response in 
vitro using stable liver cancer cell lines with either overexpression or knockdown of HOXA13. 
 
MATERIALS AND METHODS 
Tissue microarray data and patient samples  
Tissue microarray (TMA) was constructed from formalin-fixed and paraffin-embedded (FFPE) specimens 
using a custom-built instrument (Beecher Instruments, Silver Spring, MD) as previously described.27 
Specimens were mostly collected from patients with early stage disease who were eligible for and 
underwent surgical resection without prior treatment. The TMA contained 434 tissue specimens of which 
305 were suitable for evaluation, which included 115 HCC, 82 cirrhotic liver and 108 normal liver samples 
(Supplementary Table S1). Exclusion criteria from the analysis were the absence of tissue punch, poor 
HOXA13 immunostaining quality or the lack of comprehensive clinical data. Tissue samples were retrieved 
from the archives of the Institute of Pathology, University Hospital Basel, Switzerland. Histologic grading 
and classification of HCCs and non-neoplastic liver tissue samples was performed by two experienced 
pathologists with an expertise in liver pathology (M.S.M. and L.M.T.) according to the World Health 
Organization (WHO) guidelines28 and the Edmondson & Steiner grading system.29 Additionally, samples 
were classified using the Barcelona Clinic Liver Cancer (BCLC) staging classification.30 A second cohort of 
samples comprising whole sections from 43 resected HCC samples from sorafenib-treated patients was 
obtained from the Unit of Pathology, University of Milan and Humanitas Clinical and Research Center, 
Milan, Italy (Supplementary Table S2). Histologic grading and classification of this cohort of samples was 
performed by three experienced pathologists (C.N., M.R. and L.M.T.) as described for the TMA cohort. The 
study was approved by the institutional review boards of the respective authors’ institutions. 
 
Immunohistochemistry 
Immunohistochemical (IHC) staining for HOXA13 and E-cadherin was performed on 4 µm sections of FFPE 
tissue using primary antibodies against HOXA13 (Abcam, Cambridge, UK; clone ab106503, dilution 1:200) 
and E-cadherin (Cell Marque, Rocklin, CA; clone EP000Y, ready-to-use). Specifically, sections were pre-
treated with CC1 (Ventana Medical Systems, Tucson, AZ) and incubated with primary antibodies against 
HOXA13 and E-cadherin. Staining procedures were performed on a Benchmark immunohistochemistry 
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staining system (Ventana Medical Systems, Tucson, AZ) using iVIEW-DAB as chromogen as previously 
described.31 Positive and negative controls were included in each run. Immunoreactivity was scored by two 
experienced pathologists (M.S.M. and L.M.T.) For HOXA13, TMA specimens (tissue punches) were 
analyzed by evaluating the staining intensity (0-3, Figure 1a). For HOXA13 on whole tissue sections using 
at least two non-consecutive fields, both the staining intensity (0-3) and the percentage of stained cells (i.e. 
hepatocytes) were evaluated as described by Allred et al.32 and classified as HOXA13-high and HOXA13-
low using a semi-quantitative score accounting for both staining intensity and the percentage of stained 
cells using the following formula: 
((-x0*25) + (x1*20+ x2*30+ x3*50)*75))/100 
where xi is the percentage of cells with intensity i. Sample with positive and negative scores were classified 
as HOXA13-high and HOXA13-low, respectively. 
 
Analysis of putative HOXA13 binding sites on CDH1 promoter 
The promoter sequence of the human CDH1 gene (encoding E-cadherin, Unigene ID: Hs.461086, ID of 
transcript: NM_004360) was retrieved from the DataBase of Transcriptional Start Site (DBTSS, http://dbtss-
old.hgc.jp/hg19_mm9/), encompassing the genomic regions 2000bp upstream to 400bp downstream of the 
CDH1 transcriptional start site. The CDH1 promoter sequence was scanned for the presence of putative 
binding sites of HOXA13 using the JASPAR algorithm33 (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl) and 
the frequency matrix model (MA0650.1) corresponding to the human HOXA13 (Supplementary Figure 
S1a). The default relative score cut-off of 0.8 was used. Based on the results from JASPAR, a graphical 
representation of the distribution of putative binding sites of HOXA13 on the promoter region of CDH1 gene 
was obtained using ConSite service (http://consite.genereg.net/). 
 
HOTTIP RNA in situ hybridization 
Single color RNA in situ hybridization (ISH) was performed using the RNAscope® 2.0 HD Red 
Chromogenic Reagent Kit (Advanced Cell Diagnostics, Newark, CA) per the manufacturer’s guidelines. 
Paired double-Z oligonucleotide probes were designed against Hs-HOTTIP RNA (Catalog number 400133, 
Advanced Cell Diagnostics, Newark, CA) using custom software as described previously.34 GenBank 
accession numbers, number of probe pairs, and probe regions are: NR_037843, 20 pairs, nucleotides 388-
1386. 4 µm sections of FFPE tissue were incubated at 60°C for 1 hr prior to use. After de-paraffinization 
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and dehydration, the tissues were air-dried and treated with peroxidase blocker before boiling at 100-104°C 
in a pre-treatment solution for 15 min. Protease was then applied at 40°C for 30 min. Target probes were 
hybridized at 40°C for 2 hrs. All hybridizations were performed in a HybEZ system (Advanced Cell 
Diagnostics, Newark, CA) at 40°C. Hybridization signals were detected by chromogenic precipitate 
development and RNA staining signal was identified as red dots. Following the RNAscope assay, samples 
were counterstained for 2 min with 50% Gill’s Hematoxylin diluted in dH2O. Each sample was quality 
controlled for RNA integrity with a probe specific to the housekeeping gene cyclophilin B (PPIB); only 
samples with an average of >4 dots per cell were included for analysis. Negative control background 
staining was evaluated using a probe specific to the bacterial dapB gene. To verify that the RNAscope 
method was performed with technical accuracy, references slides consisting of FFPE HeLa cells were 
tested with PPIB and dapB in parallel with tissue samples. Staining intensity was scored on the 4-point 
scale (i.e. 0-3) by two experienced pathologists (M.S.M and L.M.T.) as for HOXA13 IHC staining intensity. 
 
Cell lines maintenance and generation of stable clones 
Liver cancer-derived cell lines SNU-449 and HepG2 were obtained from the Laboratory of Experimental 
Carcinogenesis (Bethesda, MD), authenticated by short tandem repeat profiling as previously described35 
and tested for mycoplasma infection using a PCR-based test (ATCC). All cell lines were maintained under 
the condition as recommended by the provider. Total RNA and proteins were extracted from cells at 75% 
confluence using TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacture’s guidelines. SNU-449 
and HepG2 cells were transfected as described by Wang et al.36 to generate stable HOXA13-expressing 
cell lines.  
 
Stable HOXA13 knockdown cells were obtained using the TALEN. Specifically, 13x104 cells were plated in 
6-well plate and after 24 hr cells were transfected with lipofectamine3000 (Thermo Fisher Scientific, 
Reinach, CH) according to the manufacturer’s procedure with pcDNA3.1+ containing the full-length human 
cDNA of HOXA13 and empty vector as control.22 The cells were selected with 50 ug/ml of G418 (Gibco) for 
72 hrs. For the knocking down of HOXA13, SNU-449 and HepG2 were simultaneously transfected with 
TAL2209/2209, a gift from Keith Joung (plasmids # 36672 and #36671, Addgene, Cambridge, MA).37 24 
hrs after transfection, cells were plated in 96-well plate using a dilution of 1 cell/well. 
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Relative expression of HOXA13 by qRT-PCR 
cDNA was synthesized from 1 μg of total RNA using Superscript II RNase H-reverse transcriptase 
(Invitrogen, Carlsbad, CA). HOXA13 expression was assessed using the TaqMan® Probe-Based Gene 
Expression Analysis (Applied Biosystems, Foster City, CA; probe Hs00426284_m1). Measurements were 
normalized using GAPDH and 18S levels as reference. The fold change in gene expression was calculated 
using the standard ∆∆Ct method as previously described.23, 38 All reverse-transcriptase reactions, including 
no-template controls, were run on an Applied Biosystem 7900HT thermocycler. All samples were analyzed 
in triplicate. 
 
Soft-agar colony assay, proliferation assay and in vitro sorafenib exposure  
Soft agar colony formation assay was performed as previously described.39 Specifically, 103 cells were 
plated in 60mm dishes in a solution containing Dulbecco’s modified Eagle’s medium 2X (Thermo Fisher 
Scientific, Foster City, CA), TPB Buffer (Thermo Fisher Scientific) and 1.25% of Noble Agar (Difco, Franklin 
Lakes, NJ). Cells were harvested and counted, and a layer of 7ml solution containing Noble Agar was left 
to polymerize on the bottom of the dishes. Meanwhile cells were diluted in 2ml of the same solution, plated 
and left growing for 2 weeks in the incubator. Pictures of four different fields were taken using an inverted 
microscope and cell colonies were counted and measured in size using the ImageJ software (Version 
1.49). Colonies were classified into three groups based on thresholds defined using the size distribution 
(arbitrary units) of the control group as small (first quartile), medium (2nd and 3rd quartiles) and large (4th 
quartile).  
 
Cell proliferation was assayed using the xCELLigence system (RTCA, ACEA Biosciences, San Diego, CA). 
Background impedance of the xCELLigence system was measured for 12 sec using 50 μL of room 
temperature cell culture media in each well of E-plate 16. SNU-449 and HepG2 cells were grown and 
expanded in tissue culture flasks as previously described.40 After reaching 75% confluence, the cells were 
washed with PBS and detached from the flasks using a short treatment with trypsin/EDTA. 10,000 cells 
were dispensed into each well of an E-plate 16. Growth and proliferation of the cells were monitored every 
15 min up to 72 hrs via the incorporated sensor electrode arrays of the xCELLigence system, using the 
RTCA-integrated software according to the manufacturer’s parameters. 
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In vitro sorafenib exposure experiments were carried out as described by Rothweiler et al.41 Briefly, cells 
were grown as above and 24 hrs after cell seeding, sorafenib at final concentration of 10 μM or 20 μM or 
DMSO (0.1% v/v) was added. Cell growth was assayed for up to 72 hours. Data analysis and data 
normalization to the time before sorafenib/ DMSO addition was carried out using the RTCA Software 
1.2.1.1002. Cell index values from 3 replicate experiments were normalized to DMSO, which was set as 
100%. 
 
Migration Assay.  
Migration assay was performed with CIM plates using the xCELLigence technologies (OLS OMNI Life 
Science, Basel, Switzerland). Stably transfected cells were detached and counted. 3x104 cells were plated 
in each well according to manufacturer’s instruction and migration was assessed 12, 24 and 36 hrs after 
seeding. 
 
Statistical analysis 
For statistical analysis, the Chi-squared test (χ2 test) and Fisher's exact test for categorical variables and 
Mann-Whitney U/multiple t-tests/t-tests for continuous variables were used. Patient survival was assessed 
using the Kaplan–Meier method and analyzed using the log-rank test. Correlation tests were performed 
using Spearman correlation. All tests were two-sided and P-values ≤0.05 were considered statistically 
significant. Analyses were performed using GraphPad 6.0 (Prism, La Jolla, CA) and SPSS (version 24, 
IBM, San Francisco, CA). 
 
RESULTS 
HOXA13 protein is increased in poorly differentiated and more aggressive HCCs 
In a previous study, our group reported an upregulation of the RNA expression levels of the HOXA13 gene 
in the majority of HCCs analyzed.22  To corroborate and to extend this finding to the protein level, we 
investigated, by means of IHC on a TMA, HOXA13 levels on a large cohort of HCC (n=115), cirrhotic liver 
(n=108) and normal liver (n=82) specimens (Supplementary Table S1). Samples were evaluated according 
to their staining intensity (Figure 1a). Our analysis revealed that HOXA13 was expressed (i.e. intensities 1, 
2 or 3) in 10% (8/82) of normal liver, 18% (19/108) of cirrhotic liver and 42% (48/115) of HCC specimens 
with a monotonic increase from normal liver tissues to cirrhotic tissues to HCCs (P <0.001, Chi-squared 
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test, Figure 1b). Stratification based on the individual HOXA13 IHC intensity scores in HCCs showed that 
those with high HOXA13 expression (intensity 3) were associated with the highest proportion (29%) of 
poorly differentiated tumors (P <0.001, Chi-squared test, Figure 1c). Altogether, these results highlighted 
that: i) HOXA13 positivity is more frequent in HCCs compared to normal and cirrhotic livers and ii) high 
HOXA13 expression is associated with high tumor grade.  
 
Considering our previous finding that HOXA13 expression was associated with metastasis in HCC,22 we 
evaluated the expression of E-cadherin, a master regulation of the metastatic process,42 in the same set of 
samples. We observed that HOXA13-positive HCCs had lower percentages of E-cadherin-positive cells 
compared to HOXA13-negative HCCs, cirrhotic liver and normal liver specimens (mean of positive cells 
48% vs 65%, 68% and 69%, respectively, all P <0.05, Mann-Whitney U tests, Figure 1d). Stratification of 
HCCs based on HOXA13 staining intensity scores showed that E-cadherin levels were inversely correlated 
with HOXA13 expression (all P <0.05, Mann-Whitney U tests, Figure 1e).  
 
To determine if there is a causal link between the inverse expression pattern of HOXA13 and E-cadherin, 
we performed in silico and in vitro experiments to determine if HOXA13 could directly regulate the 
expression of E-cadherin (encoded by CDH1). Using the JASPAR algorithm33, we identified several 
putative HOXA13 binding sites on the CDH1 promoter sequence, in particular in the region 2000bp to 
500bp upstream of the CDH1 transcriptional start site (Supplementary Figure S1), suggesting that HOXA13 
may directly interact with the CDH1 promoter. Indeed, upon stable overexpression of HOXA13 in the HCC 
HepG2 cell line, we observed a decrease in E-cadherin and, conversely, an increase in N-cadherin 
expression (Figure 1f). In line with a previously published report43, our in silico and in vitro experiments 
suggest a possible role for HOXA13 in the regulation of epithelial-to-mesenchymal transition in directly 
binding to E-cadherin. 
 
Taken together, these results suggest that HOXA13 overexpression is associated with a more 
undifferentiated and aggressive tumor phenotype in HCC and we provided additional evidences that 
HOXA13 may regulate E-cadherin. 
 
HOXA13 protein level is associated with HCC patient survival  
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To explore whether HOXA13 protein levels were associated with the outcome of HCC patients as we 
previously demonstrated for HOXA13 mRNA levels,22 we examined the patient overall survival (OS) and 
disease-free survival (DFS) for our cohort of TMA HCC samples (n=115, Supplementary Table S1). 
Patients with HOXA13-positive HCC had shorter OS compared to those with HOXA13-negative disease 
(median 52 vs 65 months, P =0.03, log-rank test, Figure 2a). However, we found no statistical difference in 
DFS between patients with HOXA13-positive and HOXA13-negative HCC (median 16 vs 20 months, P 
=0.33, log-rank test, Supplementary Figure S2a). Similarly, comparing the OS and DFS stratified according 
to HOXA13 IHC staining intensities demonstrated that patients with HCCs with the highest IHC intensity 
(i.e. 3) had the worst OS, but no difference was observed in DFS (P =0.04 and P =0.24, respectively, log-
rank tests, Figure 2b and Supplementary Figure S2b). Focusing on patients with BCLC grade C HCC, since 
this is the only group eligible for sorafenib treatment, we found that patients with HOXA13-positive HCC 
had worse OS than those with HOXA13-negative disease (median 20 vs 24 months, P =0.05, log-rank test, 
Figure 2c). 
 
To extend these results to sorafenib-treated patients, we obtained whole tissue sections of an independent 
cohort composed of late stage sorafenib-treated HCCs (Supplementary Table S2) and classified them as 
HOXA13-high and –low based on a semi-quantitative score, taking into account the staining intensity and 
the proportion of positive cells (Methods). In accordance with the results obtained from patients with 
untreated HCCs, sorafenib-treated patients with HOXA13-positive HCCs showed decreased OS compared 
to patients with HOXA13-negative disease (median 31 vs 41 months, P =0.05, log-rank test, Figure 2d).  
 
These results suggest the HOXA13 protein expression in HCC is associated with OS in patients treated or 
untreated with sorafenib. 
 
HOXA13 expression overlaps with HOTTIP in HCC samples 
Based on gene expression array data, we previously showed that HOXA13 overexpression in HCC is 
associated with concomitant HOTTIP upregulation.22 To determine whether HOXA13 is upregulated in the 
same population of cells as HOTTIP, we performed HOXA13 IHC and HOTTIP RNA in situ hybridization 
(ISH) on consecutive sections of 16 resected HCCs from the sorafenib-treated cohort (Supplementary 
Table S2). We found that both HOXA13 and HOTTIP were heterogeneously expressed in 71% of cases 
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analyzed. Comparing the expression patterns, we observed that HOXA13 and HOTTIP were expressed in 
virtually the same populations of hepatocytes (Figure 3a) and that the percentages of HOXA13-positive and 
HOTTIP-positive cells demonstrated a significant correlation (r =0.91, P <0.0001, Spearman correlation 
test, Figure 3b-c). 
 
HOXA13 overexpression enhances cell aggressiveness in vitro 
In line with the observations that HOXA13 expression is increased in HCCs compared to non-tumoral livers   
and in poorly differentiated HCCs compared to moderately and well differentiated HCCs, our previous 
results demonstrated that transient in vitro HOXA13 overexpression in liver cancer cells resulted in 
increased proliferation whereas HOXA13 inhibition strongly reduced cell proliferation.22 Therefore, we 
sought to investigate if stable ectopic HOXA13 overexpression would have oncogenic properties in in vitro 
models. We generated liver cancer-derived cell line SNU-449 clones that stably overexpressed HOXA13, 
as verified by qRT-PCR (Supplementary Figure S3a). To test whether the cells that overexpressed 
HOXA13 displayed a more aggressive phenotype, we performed a colony formation assay on soft agar and 
evaluated the number and size of the resulting colonies (Figure 4a). Compared to the untransfected cell 
lines and the empty vector controls, SNU-449 overexpressing HOXA13 displayed larger colonies (P <0.05, 
Mann-Whitney U test, Figure 4b) and a higher number of colonies per analyzed field (P <0.05, Mann-
Whitney U test, Figure 4c). Additionally, we performed a migration assay on SNU-449 and HepG2 stably 
overexpressing HOXA13 and observed that forced expression of HOXA13 resulted in increased cell 
migration (both P<0.05, Figure 4 d-e) in both cell lines, thus supporting and corroborating our hypothesis 
that HOXA13 promotes epithelial-to-mesenchymal transition. 
 
Taken together our results suggest that, in addition to increasing cell proliferation, HOXA13 overexpression 
also enhances cell aggressiveness and migration in vitro. 
 
HOXA13 level modulates sorafenib sensitivity in vitro  
To provide a functional basis for our observation that sorafenib-treated patients with high HOXA13 levels in 
their HCCs had worse survival, we sought to investigate the impact of HOXA13 modulation in HCC-derived 
cell lines upon sorafenib exposure in vitro. In addition to the liver cancer-derived cell lines (SNU-449 and 
HepG2) with stable HOXA13 overexpression using pCMV-vector, we also generated two cell lines (SNU-
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449 and HepG2) with HOXA13 knockdown using TALEN, as verified by qRT-PCR (Supplementary Figure 
S3). To define the appropriate dose of sorafenib in vitro, we performed a titration experiment using 
untransfected SNU-449 and HepG2 (Supplementary Figure S4) and observed a significant inhibition of cell 
viability at 20 μM sorafenib compared to other concentrations (P <0.05, multiple t-test, Supplementary 
Figure S4). We then compared the proliferation indices of treated and untreated cells with and without 
HOXA13 overexpression using the xCelligence system up to 72 hours after sorafenib exposure. In 
accordance with our previous results,22 in the absence of sorafenib, HOXA13-overexpressing cells 
displayed increased cell proliferation compared to the vector control (P <0.01, multiple t-test, Figure 5a/c). 
By contrast, sorafenib treatment significantly reduced cell proliferation in the vector control but had no effect 
in HOXA13-overexpressing cells (P <0.01 and P >0.05, respectively, multiple t-tests, Figure 5a/c).  
 
Conversely, when we compared the untreated cells with and without HOXA13 knockdown, HOXA13-
knockdown cells had lower cell proliferation than cells with TALEN control in both SNU-449 and HepG2 
(both P <0.01, multiple t-tests, Figure 5b/d). On the other hand, upon sorafenib exposure, cell proliferation 
was significantly reduced in HOXA13 knockdown cells compared to the cells with TALEN control in both 
cell lines (both P <0.01, multiple t-tests, Figure 5b/d). Overall, these results provide evidence that 
overexpression of HOXA13 modulates sorafenib response in HCC in vitro models. 
 
DISCUSSION  
In this study, we reported that HOXA13 protein level increased monotonically from normal liver to cirrhotic 
liver to HCC. We also observed that HOXA13-positive HCCs were preferentially poorly differentiated and 
had fewer E-cadherin-positive cells. In addition, we demonstrated that HOXA13 positivity is associated with 
worse overall survival, but not disease-free survival, which we confirmed in a second cohort consisting of 
sorafenib-treated patients. Furthermore, we showed that HOXA13 and HOTTIP were co-expressed in the 
same population of neoplastic hepatocytes in HCC. Finally, using liver cancer-derived cell lines, we 
demonstrated that HOXA13 expression enhances cell aggressiveness and modulates sorafenib response 
in vitro.  
 
Based on gene expression data, we previously reported that HOXA13 is significantly upregulated in HCC.22, 
23 In this work, by analyzing a large cohort of HCC samples (n=115), we extended our results to the protein 
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level showing consistent HOXA13 overexpression in HCCs. This observation complements our previous 
results on the mRNA level,22, 23 is in line with the findings of another group on the protein level24 and further 
highlights that HOXA13 is deregulated in a subgroup of poorly differentiated (i.e. high Edmondson grade) 
HCCs. Additionally, we observed that HOXA13-positive HCCs harbored fewer E-cadherin-positive cells. 
The loss of E-cadherin has been linked to the formation of metastases through the process of epithelial-to-
mesenchymal transition44 and several groups recently reported that HOXA13 expression promotes cell 
invasive properties, for instance in glioma by activating the Wnt and TGF-β pathways.21 Our observation of 
HOXA13-positive HCCs displaying a more aggressive phenotype is thus in line with our previously 
described association between high HOXA13 level and metastatic incidence22 and the association with 
worse prognosis in terms of OS in these patients. HOXA13 positivity has been associated with unfavorable 
survival in HCCs24 as well as in other tumor entities such as esophageal squamous cell carcinoma,26, 45 
gastric cancer46 and paediatric acute lymphoblastic leukaemia.18, 47, 48 In contrast to the previous study in 
which the authors found associations of HOXA13 expression with both OS and DFS,24 we found that 
HOXA13 expression was only associated with unfavorable OS, but not DFS, in two independent cohorts, 
one of which was a cohort of patients with sorafenib-treated, late-stage disease. 
 
The results from our in vitro experiments provide functional evidence for the association observed between 
HOXA13 overexpression and the more aggressive and less differentiated phenotype in HCCs. We 
observed loss of E-cadherin upon HOXA13 overexpression and identified putative HOXA13 binding sites in 
the CDH1 promoter, suggesting that HOXA13 may have a direct role in the regulation of E-cadherin 
expression. Additionally, we observed increased colony formation and migration potential in cell lines 
overexpressing HOXA13, demonstrating that HOXA13 confers a more aggressive phenotype. In terms of 
sensitivity to sorafenib, forced expression of HOXA13 resulted in reduced sensitivity in vitro whereas 
knockdown of HOXA13 had the opposite effect. Given the role of HOXA13 in regulating E-cadherin and the 
previously published results49 suggesting that epithelial-to-mesenchymal transition plays a pivotal role in 
modulating drug resistance, one can speculate that HOXA13 may affect sensitivity to sorafenib through the 
regulation of the epithelial-to-mesenchymal transition process. Indeed, the reduced sensitivity to sorafenib 
may be related to the loss of E-cadherin and hence an epithelial phenotype. Conversely, upregulation of 
HOXA13 may also affect drug response to multiple drugs in multiple cancer types as HOXA13 
overexpression has also been reported to result in gemcitabine resistance in pancreatic cancer.43 These 
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results provide a functional basis for the suboptimal response of the subset of patients with HOXA13-
positive disease and the observed reduced OS in this group of patients.  
 
Several studies previously demonstrated that HOXA13 and HOTTIP expression are highly correlated.50-53 
Specifically, we reported that HOTTIP activates HOXA13 through epigenetic mechanisms including DNA 
methylation and histone modifications22 and Wang et al. described that, in the Cs12 gastric cells, HOTTIP 
knockdown attenuates the recruitment of WDR5 and MLL1 and promotes DNMT3B localization on the 
HOXA13 promoter.50 Here by analyzing HOXA13 IHC and HOTTIP ISH on consecutive HCC sections, we 
showed that HOXA13 and HOTTIP displayed intra-tumor heterogeneous pattern of expression and their 
concomitant overexpression was found in the same populations of transformed hepatocytes. To the best of 
our knowledge, this is the first in situ characterization of the pattern of HOTTIP expression in human 
tissues. Given the increased recognition of the role of lncRNAs in cancer,54 this observation and the 
technique are of significant interest. We foresee that in situ characterization of HOTTIP expression will 
enable the identification of the specific subpopulations of transformed or malignant cells that express 
HOTTIP.  
 
There are several limitations to our study. Our first and larger cohort of resected samples consisted of TMA 
punches rather than whole sections, and thus the observed expression may not be representative of the 
individual tissue samples. To account for intra-tumor heterogeneous expression of HOXA13, for the second 
cohort for which whole sections were available, we used a semi-quantitative score that accounts for both 
staining intensity and the percentage of cells for each staining intensity. In addition, the number of patients 
with BCLC stage C disease and late-stage sorafenib-treated patients for survival analysis was small. It 
should be noted that, despite the small cohorts, we saw a consistent association of HOXA13 
overexpression with worse prognosis in both cohorts. It should also be noted that access to such 
collections of specimens with the associated outcome data is extremely limited. Finally, our results have not 
provided mechanistic insight into the association of HOXA13, HOTTIP and E-cadherin expression and the 
effect of HOXA13 expression on sorafenib sensitivity. Although we found that HOTTIP and HOXA13 are 
expressed in same population of cells, we have not provided direct evidence to support the hypothesis that 
HOTTIP regulates HOXA13 expression. Due to the cis-regulatory mechanism of HOTTIP, the physical 
proximity of HOTTIP to the HOX genes (including HOXA13) on the genome is essential for its regulatory 
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activity. Indeed, it has been demonstrated by,36 that ectopic HOTTIP expression driven by retroviral 
insertion sites scattered randomly throughout the genome is not sufficient to induce 5’ HOXA genes. Future 
experiments using genome editing technology to investigate the regulatory role of HOTTIP would be of 
great interest. 
 
To conclude, using a combination of clinico-pathologic and protein expression data obtained from two 
independent cohorts of HCC patients, as well as in vitro experiments, we provided evidence for a role of the 
molecular axis comprising HOXA13/HOTTIP in HCC development and response to sorafenib.   
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FIGURES LEGENDS 
Figure 1: HOXA13 is expressed in a subset of aggressive HCCs and is inversely correlated with E-
cadherin expression. (a) Representative micrographs of HOXA13 IHC with different staining intensities. 
(b) Percentages of HOXA13-positive and-negative normal, cirrhotic and tumoral livers. (c) HOXA13 
intensity in poorly, moderately and well differentiated HCCs. (d) E-cadherin expression levels in normal, 
cirrhotic, HOXA13-negative and HOXA13-positive tumoral livers. (e) E-cadherin expression levels in 
normal, cirrhotic and tumoral livers according to HOXA13 intensities. (f) E-cadherin and N-cadherin protein 
levels upon overexpression of HOXA13 in HepG2 cell lines. P-values ≤0.05 were considered statistically 
significant. *: P-values ≤0.05; Error bars, s.d. of the mean. 
 
Figure 2: High HOXA13 expression is associated with poor overall survival in patients with HCC. 
Overall survival of 115 HCC patients, (a) stratified into HOXA13-negative (staining intensity 0) and 
HOXA13-positive (staining intensity 1/2/3) or (b) stratified according to HOXA13 staining intensities. (c) 
Overall survival of 26 BCLC stage C HCC patients stratified into HOXA13-negative (staining intensity 0) 
and HOXA13-positive (staining intensity 1/2/3). (d) Overall survival of 43 HCC sorafenib-treated patients, 
stratified into HOXA13-negative (staining intensity 0) and HOXA13-positive (staining intensity 1/2/3). 
Statistical comparisons were performed using log-rank tests. P-values ≤0.05 were considered statistically 
significant. 
 
Figure 3: HOXA13 and HOTTIP expression patterns in HCC. (a) Representative micrographs of 
HOXA13 IHC and HOTTIP ISH stained HCCs. (b) Heat map displaying the percentage of HOXA13-positive 
and HOTTIP-positive cells. (c) Spearman correlation analysis performed for the percentages of HOTTIP-
positive and HOXA13-positive cells. 
 
Figure 4: Effect of HOXA13 overexpression on cell transformation in in vitro models. (a) 
Representative micrographs of colonies, (b) distribution of sizes of the colonies and (c) number of colonies 
per field in control SNU-449 cells and SNU-449 cells stably overexpressing HOXA13. (d-e) Migration 
potential in SNU-449 and HepG2 cell lines at 12,24 and 36hrs in stable HOXA13 overexpressing cells. All 
experiments were performed in triplicates. Error bars, s.d. of the mean. Statistical comparisons were 
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performed using unpaired t-tests with Welch correction. P ≤0.05 were considered statistically significant. *: 
P ≤0.05; ns: not significant. 
 
Figure 5: HOXA13 modulates sorafenib response in HCC cells. Effect of sorafenib treatment in cells 
with (a-c) stable overexpression of HOXA13 (SNU-449 and HepG2) or (b-c) knockdown of HOXA13 (SNU-
449 and HepG2) compared to the untransfected controls. Quantification was performed using a 
spectrophotometer. All experiments were performed in triplicates. Error bars, s.d. of the mean. Statistical 
comparisons were performed using Holm-Šídák-corrected multiple t tests an. P ≤0.05 were considered 
statistically significant. **: P ≤0.01. 
 





